Company news: PhRMA, Amgen

Share this article:
A report by PhRMA suggests that the industry is looking at a robust pipeline. Among the trade group's findings: more than 5,000 new medications are being studied and 70% are “potential first-in-class medicines,” meaning a high potential for patent-loss replacements. The research, however, is not necessarily focused solely on broad-based applications: the interest group said that rare diseases, for example, continue to garner attention, with about 140 potential medicines being researched in the past decade, compared to 64 twenty years ago.

Clinical trial results indicate Amgen's anemia drug Aranesp is not a help for heart failure patients, reported Forbes. The Phase III testing started in 2006 with 2,278 patients, and today's announcement indicates the results missed the primary endpoint. Separately, the company said it will build a $200 million new manufacturing plant in Singapore for monoclonal antibodies.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.